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The use of probiotics as a food supplement has gained tremendous interest in the last few years as
beneficial effects were reported in gut homeostasis and nutrient absorption but also in immunocompro-
mised patients, supporting protection from colonization or infection with pathogenic bacteria or fungi. As
a treatment approach for inflammatory bowel diseases, a suitable probiotic strain would ideally be one
with a low immunogenic potential. Insight into the immunogenicities and types of T-cell responses induced
by potentially probiotic strains allows a more rational selection of a particular strain. In the present study,
the bacterial strains Bifidobacterium breve (NumRes 204), Lactobacillus rhamnosus (NumRes1), and Lac-
tobacillus casei (DN-114 001) were compared concerning their capacity to induce inflammatory responses
in terms of cytokine production by human and mouse primary immune cells. It was demonstrated that the
B. breve strain induced lower levels of the proinflammatory cytokine gamma interferon (IFN-) than the
tested L. rhamnosus and L. casei strains. Both B. breve and lactobacilli induced cytokines in a Toll-like
receptor 9 (TLR9)-dependent manner, while the lower inflammatory profile of B. breve was due to
inhibitory effects of TLR2. No role for TLR4, NOD2, and C-type lectin receptors was apparent. In
conclusion, TLR signaling is involved in the differentiation of inflammatory responses between probiotic
strains used as food supplements.
In recent years, probiotic supplements have been suggested
to provide health benefits. Subsequently, the use of specific
probiotic strains as safe supplements for human consumption
has been approved. Probiotic strains are classified as being live
microorganisms which, when administered in sufficient
amounts, confer a health benefit to the host (11). This health
benefit could comprise more efficient digestion, nutrient ab-
sorption, or higher resistance to pathogenic bacteria in the gut.
Microorganisms from the genera Lactobacillus and Bifido-
bacterium are often considered as probiotic candidates. All
these bacteria are Gram positive, (facultative) anaerobe mi-
croorganisms that are common commensals in the human gas-
trointestinal tract. These bacteria are currently used in probi-
otic dietary products, and several lines of evidence have
demonstrated their beneficial effects on gut homeostasis (6, 16,
20, 38, 44). In addition, mouse studies have been conducted to
investigate the immunomodulatory capacity of these potential
probiotics, with similar findings (18, 23, 43, 46). These effects
range from downregulation of cytokine responses in immune
cells to induction of apoptosis in T cells and vaccine-improving
properties (4, 7, 8, 10, 13).
Previous studies indicate that the ability of probiotics to
induce the secretion of various cytokines is mediated to a large
extent by cell wall components (13, 25, 40). Cell wall compo-
nents elicit these responses through recognition by pattern
recognition receptors (PRRs), germ line-encoded receptors
expressed on innate immune cells that are specialized to bind
these bacterial substances. Examples of these receptors, either
membrane bound or localized intracellularly, are the Toll-like
receptors (TLRs), C-type lectin receptors (CLRs) (such as
dectin 1, mannose receptor, or DC-SIGN), and nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs)
(such as the peptidoglycan receptor NOD2). For the triggering
of intracellular receptors, the process of phagocytosis is re-
quired, whereas membrane-bound receptors detect their li-
gand on the cell surface and in some cases facilitate phagocy-
tosis (2). Subsequently, downstream intracellular signaling
from these receptors results in the modulation of cytokine
responses (30).
The PRRs that are responsible for the recognition of these
strains, resulting in induction of cytokine responses and acti-
vation of the immune system, remain elusive. Therefore, in the
present study the capacity of the bacterial strains Bifidobacterium
breve (NumRes204), Lactobacillus rhamnosus (NumRes1), Lac-
tobacillus casei (DN-114 001) to induce immune responses in
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peripheral blood mononuclear cells (PBMCs) has been exam-
ined for both healthy volunteers and NOD2-deficient Crohn’s
disease (CD) patients. Furthermore, the role of several PRRs
of the innate immune system that could mediate these immune
responses, including TLRs, CLRs, and NLRs, has been inves-
tigated in both human and mouse cells.
MATERIALS AND METHODS
Subjects. Healthy volunteers and Crohn’s disease patients were recruited at
the Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. The
study was approved by the Ethical Committee of the Radboud University, and
the volunteers gave informed consent. At the time of donation, Crohn’s disease
patients homozygous for the NOD2 frameshift mutation were in a quiescent
phase, i.e., a prolonged period of at least 3 months of mild disease without
relapses or exacerbations in the absence of immunomodulatory therapy. Also,
they had received no immunomodulatory or anti-inflammatory medications for
the last 3 months.
Mice. Wild-type C57BL/6 mice were obtained from Charles River WIGA
(Sulzfeld, Germany) GmbH. TLR2 knockout mice and TLR4 knockout mice,
with a C57BL/6 background, were kindly provided by S. Akira (Osaka University,
Osaka, Japan) (42). All animal experiments were approved by the Animal Ex-
perimental Committee of Radboud University Nijmegen Medical Centre, Ni-
jmegen, Netherlands, and were performed in accordance with institutional and
national guidelines.
Reagents. Blocking monoclonal antibodies (Abs) of the innate immune recep-
tors TLR2 (clone T2.5) and DC-SIGN (clone AZND1), including the IgG1
isotype control, were purchased from eBioscience, Coulter Beckman, and R&D
Systems, respectively, and were all used in a concentration of 10 g/ml. Blocking
reagents of the receptors TLR4 (Bartonella quintana lipopolysaccharide, [31], 1
g/ml), TLR9 (CpG ODN TTAGGG, 25 g/ml; Invivogen), mannose receptor
(mannan, 100 g/ml; Sigma), and dectin 1 (laminarin, 100 g/ml; Sigma), and of
phagocytosis (cytochalasin B, 1 g/ml; Biomol International) were used.
Bacterial fermentation and enumeration. Two Lactobacillus strains
(NumRes1 and DN-114 001) and a Bifidobacterium breve strain (NumRes204)
were grown at 37°C in a 400-ml reactor containing MRS supplemented with 0.5
g/liter L-cysteine for Bifidobacteria. The pH was maintained at 6.5 by addition of
NaOH. To ensure anaerobic conditions, the headspace was flushed with N2 or a
gas mixture consisting of 5% H2, 5% CO2, and 90% N2 for Bifidobacteria.
Bacteria were harvested in the early stationary phase, washed in phosphate-
buffered saline (PBS), and stored with 20% (wt/vol) glycerol in aliquots at
80°C. Cell counts were determined by plating serial dilutions (CFU) and
fluorescent microscopy by staining with 4,6-diamidino-2-phenylindole (DAPI).
PBMC stimulation experiments. Venous blood was drawn from the cubital
vein of healthy volunteers into 10-ml EDTA tubes (Monoject). The mononuclear
cell fraction was obtained by density centrifugation of blood diluted 1:1 in
pyrogen-free saline over Ficoll-Paque medium (Pharmacia Biotech, Pennsylva-
nia). Cells were washed twice in saline and suspended in culture medium (Dul-
becco’s modified Eagle medium [DMEM], Invitrogen, CA) supplemented with
gentamicin (50 g/ml), L-glutamine (10 mM), and pyruvate (10 mM). Cells were
counted in a Coulter counter (Coulter Electronics), and the number was adjusted
to 5  106 cells/ml. A total of 5  105 mononuclear cells (MNCs) in a 100-l
volume were added to round-bottom 96-well plates (Greiner) and incubated with
either 100 l of culture medium (negative control) or B. breve, L. rhamnosus, or
L. casei (107 microorganisms/well for each) at a ratio of 20:1 bacterial cells/
MNCs for 24 h, 48 h, or 7 days, alone or in combination with one of the
above-mentioned receptor blockers or inhibitors.
Splenocyte stimulation experiments. Wild-type, TLR2KO, and TLR4KO
C57BL/6 mice were sacrificed, and spleens were collected. From each total
spleen, a cell suspension was made in culture medium (Iscove’s modified Dul-
becco’s medium [IMDM]; Invitrogen, California) supplemented with gentamicin
(10 g/ml), ultraglutamine (1 mM), and 9% fetal calf serum (FCS). A total of
2  106 splenocytes/100-l volume were added to round-bottom 96-well plates
(Greiner) and incubated with either 100 l of culture medium (negative control)
or the various bacterial strains: B. breve, L. rhamnosus, and L. casei, all in a
concentration of 4  106 microorganisms/well (bacterial cell/MNC ratio  2:1).
After 48 h of incubation at 37°C, supernatants were collected and gamma inter-
feron (IFN-) detection was performed. A limited amount of cell death was
observed (but with total viability higher than 90%), and no significant differences
were seen in cell death between the different bacterial strains.
Transfection and stimulation of TLR2-expressing HEK293 cells. Stable
TLR2-expressing HEK293 cells (Invivogen, California), containing an NF-B
luciferase reporter construct (pNIFTY; Invitrogen, California), were maintained
in DMEM plus 10% FCS and the appropriate antibiotics. Cells were seeded in
96-well plates and incubated overnight with bacteria at different ratios of cells to
bacteria. Luciferase activity present in cell lysates was determined by detecting
chemiluminescence after incubation with BriteLite (Perkin Elmer, Massachu-
setts).
Generation and stimulation of mouse BMDCs. Femurs and tibiae of female 6-
to 12-week-old C57BL/6 mice were removed and purified from surrounding
muscle tissue. The protocol used for cell isolation and bone marrow-derived
dendritic cell (BMDC) culture with only granulocyte-macrophage colony-stim-
ulating factor (GM-CSF) was adapted from previous publications (21, 22). Mod-
ifications were the following. At day zero, cells were plated in petri dishes (10 cm;
Greiner) at 4  106 cells per well. The medium contained 20 ng/ml of mouse
GM-CSF (Peprotech). At day three, 4 ml of medium was added containing 37.2
ng/ml GM-CSF. At day 6, again 1 ml of medium was added, now containing 158
ng/ml GM-CSF. Immature dendritic cells (DCs) were harvested at day seven and
used in the cytokine assay. A cell suspension was made (1 106 cells/ml), and the
cells were plated in 96-well plates. To the BMDCs either probiotics (bacterial
cell/BMDC ratio  1:1) or Pam3Cys (4 g/ml) was added. DCs were incubated
with these stimuli for either 24 h or 48 h depending on the cytokine to be
measured.
Cytokine measurements. Cytokine production capacity was measured by en-
zyme-linked immunosorbent assay (ELISA) according to the manufacturer’s
protocol. ELISA kits were purchased from R&D Systems (Minnesota) for tumor
necrosis factor alpha (TNF-), interleukin 1	 (IL-1	), and IL-17 and from
Sanquin (Amsterdam, Netherlands) for IL-6, IL-10, and IFN-. Mouse IFN-
cytokine production capacity was measured by ELISA according to the protocol
reported previously (45). In brief, MaxiSorp 96-well plates (Nunc, Roskilde,
Denmark) were coated with 1 g/ml purified rat anti-mouse IFN- (capture Ab;
BD Pharmingen) overnight at 4°C in 0.1 M carbonate buffer. Plates were washed
with 0.05% Tween-PBS and blocked with 1% bovine serum albumin (BSA)–1%
FCS in PBS for 1 h at room temperature (RT). Plates were washed, and the
samples and standards were incubated for 1 h at 37°C. Subsequently, wells were
washed and incubated with 0.5 g/ml biotin-conjugated rat anti-mouse IFN-
(clone XMG1.2; Biolegend) in 0.1% BSA–0.1% FCS in PBS for 1 h at RT,
followed by streptavidin-horseradish peroxidase (Invitrogen) and tetramethyl-
benzidine substrate (SFRI Laboratories, Berganton, France). The reaction was
stopped with 2 M H2SO4, and adsorption was measured at 450 nm using a
Bio-Rad multiplate reader (Bio-Rad Laboratories, Veenendaal, Netherlands).
Statistics. Differences in cytokine production capacity between groups were
analyzed using the Mann-Whitney U test. Differences were considered statisti-
cally significant at P values of 
0.05.
RESULTS
Cytokine production capacity of PBMCs induced by poten-
tially probiotic strains. To study the immunostimulatory ca-
pacities of the bacterial strains B. breve, L. rhamnosus, and L.
casei, PBMCs were stimulated with bacterial cells at a ratio of
20:1, and cytokines were measured at different time points.
Important differences were observed between induction of cy-
tokine production by the bacterial strains. Most importantly,
while all monocyte-derived cytokines can be induced by all
probiotic strains studied, only lactobacilli, but not B. breve,
stimulated production of IFN- (Fig. 1).
Role of membrane-bound receptors. To study the role of
particular PRRs in the cytokine responses induced by the bac-
terial strains, several PRR-specific blocking agents were ap-
plied to the PBMCs before administration of the bacterial
strains. Surprisingly, blocking of TLR2 resulted in increased
production of IL-1	, TNF-, and IFN- when cells were stim-
ulated with B. breve (Fig. 2). However, no differences were
observed when TLR2 was blocked, either in production of
IL-6, IL-10, and IL-17 (data not shown) or after stimulation
with L. rhamnosus or L. casei (Fig. 2). Stimulation of mouse
BMDCs with Pam3Cys or either Lactobacillus strain also dem-
onstrated a minor role for TLR2 in recognition of these strains
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(Fig. 3A). Accordingly, additional experiments with TLR2-
transfected HEK293 cells revealed that B. breve but not L.
rhamnosus or L. casei induces TLR2 signaling (Fig. 3B). Block-
ing of TLR4 had no effect on cytokine production. These
experiments were also performed with mouse splenocytes, ei-
ther wild type, TLR2 knockout (KO), or TLR4 KO. Consistent
with the human data, IFN- responses in TLR2 KO cells but
not in TLR4 KO cells were different from those in wild-type
cells after stimulation with B. breve (Fig. 3C). Compared to the
human data, the TLR2 KO splenocytes also exhibited a further
increase in the production of IFN- relative to results with
wild-type splenocytes after stimulation with L. rhamnosus and
L. casei, whereas the TLR4 KO cells did not. Blocking the
C-type lectin receptors dectin 1, mannose receptor, and DC-
SIGN did not significantly influence probiotic-induced cyto-
kine production (data not shown).
Role of intracellular receptors. Microbial recognition at the
level of the cell membrane is complemented by pattern recog-
nition in the intracellular compartment by TLRs (e.g., TLR9)
or NLRs (e.g., NOD2). Therefore, the role of phagocytosis was
studied by using the phagocytosis inhibitor cytochalasin B.
Cytochalasin B decreased cytokine responses for virtually all
cytokines, suggesting an important role for intracellular recog-
nition receptors (Fig. 4). Therefore, the role of intracellular
PRRs, such as TLR9 and NOD2, in recognition of these bac-
terial strains was studied. Blocking of the TLR9 receptor re-
sulted in a profound decrease in IL-10 and IFN- responses
after stimulation of cells with either bacterial strain (Fig. 5).
FIG. 1. Cytokine production capacity of PBMCs collected from healthy volunteers and stimulated with the bacterial strains for 24 h (IL-1	,
TNF-, and IL-6), 48 h (IL-10 and IFN-), or 7 days (IL-17). Values are means  SEM; n  4; *, P 
 0.05 compared to results for stimulation
with L. rhamnosus or L. casei.
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For the other cytokines measured, TNF-, IL-1	, and IL-6
concentrations revealed no differences between the conditions
(data not shown). To assess the role of the intracellular PRR
NOD2, cells from healthy subjects with functional NOD2 were
compared with cells obtained from Crohn’s disease (CD) pa-
tients that are homozygous for the 1007fsinsC frameshift mu-
tation in NOD2, leading to a loss of function of the protein.
These analyses revealed no apparent differences between the
two groups after stimulation of these cells with the bacterial
strains (Fig. 6).
DISCUSSION
Nowadays, dietary products are widely supplemented with
probiotics, i.e., live microorganisms that may have the ability to
provide a health benefit to the host. Desirable features of a
FIG. 2. Cytokine production capacity of TNF-, IL-1	, and IFN- by PBMCs obtained from healthy volunteers and stimulated with the
bacterial strains together with a TLR2 blocking antibody or a TLR4 inhibitor (inh). Values are means  SEM; n  6; *, P 
 0.05.
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probiotic strain are protective colonization of the intestinal
tract and increasing efficiency of digestion and nutrient absorp-
tion but also a low capacity to cause immune responses to
deviate toward Th1 and/or Th17 immune responses, which are
associated with intestinal pathology (32, 37, 39). Hence, the
potential of probiotics as a therapeutic moiety in diseases in-
volving the gastrointestinal tract (e.g., infections, inflammatory
bowel disease, and colon cancer) has been suggested (12, 33,
47). The rational use of probiotics in health and disease, how-
ever, needs a detailed understanding of the recognition path-
ways that can activate host defense by probiotics.
The potential of probiotics to modulate immune responses
may represent an important factor for their therapeutic appli-
cation. In fact, it is known that the release of TNF- by in-
flamed Crohn’s disease mucosa can be significantly reduced by
coculture with L. casei DN-114 001 (5). More specifically, L.
casei can counteract the proinflammatory effects of Escherichia
coli on Crohn’s disease-inflamed mucosa by specific downregu-
lation of key proinflammatory mediators (19). In the present
study, we compared the inflammatory properties of three dif-
ferent bacterial strains, B. breve NumRes204, L. rhamnosus
NumRes1, and L. casei DN-114 001, which belong to genera
that are all widely used strains in dietary products, in their
capacity to evoke and thereby skew immune responses toward
distinct T-helper-mediated responses (i.e., immune deviation).
Compared with lactobacilli, B. breve was less capable of induc-
ing IFN- responses in human primary immune cells. The
differential stimulation of cytokine production by B. breve and
lactobacilli was mediated by differences in recognition by
PRRs with either stimulatory or inhibitory effects on cytokine
responses.
Specific blocking of particular PRRs enabled us to eluci-
date what receptors are involved in the activation of cyto-
kine production. The first important observation was that
cytokine induction by both B. breve and the lactobacilli is
strongly dependent on TLR9. Blocking of TLR9 resulted in
FIG. 3. (A) Production of IL-12, IL-10, and TNF- after stimulation of mouse bone marrow-derived dendritic cells with Pam3Cys, L.
rhamnosus, or L. casei for 24 or 48 h. Values are means SEM; n 4. (B) NF-B activity after overnight stimulation of TLR2-transfected HEK293
cells with different CFU/cell ratios of B. breve, L. rhamnosus, or L. casei. Fold induction was calculated as the ratio of experimental activity to
control activity. Values are means  SD; n  4. (C) Cytokine production capacity of IFN- by splenocytes obtained from wild-type (WT),
TLR2KO, and TLR4 KO mice stimulated with the bacterial strains. Values are means  SEM; n  6; *, P 
 0.05.
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severely decreased production of IL-10 and IFN-, indicat-
ing that these bacterial strains contain immune-stimulatory
double-stranded DNA (dsDNA) containing unmethylated
CpG sequences. In contrast, no differences were observed
when the action of other PRRs, such as TLR4, dectin 1,
mannose receptor, DC-SIGN, and NOD2, was inhibited,
indicating that these receptors have a minor role in recog-
nition of bacterial strains. The role of TLR9 in recognition
of bacterial (3, 14) and fungal (26, 34) DNA is well known;
however, its role in the induction of innate immune re-
sponses by probiotics in primary human cells had not been
demonstrated until now.
Recognition of B. breve by TLR2 had an effect opposite to
that with TLR9. Blocking of TLR2 with a specific antibody
stimulated cytokine responses induced by B. breve, including
TNF-, IL-1	, and IFN-. Interestingly, no role for TLR2
could be demonstrated in L. rhamnosus- and L. casei-induced
cytokine responses, indicating either that these bacteria lack
TLR2 ligands in their cell wall or, perhaps more likely, that
potential TLR2 ligands are masked. Of note, bone marrow-
FIG. 4. Cytokine production capacity for TNF-, IL-1	, IL-6, IL-10, and IFN- by PBMCs obtained from healthy volunteers and stimulated
with the bacterial strains in the absence or presence of cytochalasin B. Values are means  SEM; n  6; *, P 
 0.05.
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derived murine dendritic cells, which are highly susceptible to
TLR2 agonists, also failed to elicit noteworthy cytokine re-
sponses after exposure to these bacterial strains. In addition,
data from TLR2-overexpressing human embryonic kidney
(HEK293) cells containing an NF-B reporter construct
showed NF-B induction upon incubation with B. breve
whereas L. rhamnosus and L. casei were unable to do so. To
complement and support the human data, additional experi-
ments were performed with mouse splenocytes that were either
wild type or deficient in TLR2 or TLR4. In these experiments,
IFN- production was increased in TLR2 KO cells but was
similar in TLR4 KO cells to that in the wild type, which is
consistent with the human data. These findings suggest that
TLR2 induces an intracellular inhibitory signal to downstream
pathways that elicit cytokine production, such as the TLR9
pathway. Indeed, this anti-inflammatory role of TLR2 has been
demonstrated before, both in vitro and in vivo (1, 9, 35, 36).
Moreover, TLR2 has also been implicated in the induction of
regulatory T-cell responses, further emphasizing the immuno-
suppressive potential of TLR2 signaling (27, 28, 41). Also, a
Bifidobacterium strain has been shown to be able to induce
T-regulatory cells (23). However, it remains to be elucidated
whether TLR2 is involved in this process, although previously
an immunoregulatory role of TLR2 in recognition of probiotic
strains was indeed described (15, 17, 48).
When considering the potential therapeutic applications of
these probiotic strains, one could draw useful information from
the in vitro features of these strains. The data presented here
suggest that B. breve may be more suitable than Lactobacilli in
the context of inflammatory bowel diseases (and especially
Crohn’s disease), based on its lower inflammatory potential.
Th1 responses, as reflected by IFN- production, are poorly
induced by B. breve, while they are known to be crucial for the
pathogenesis of Crohn’s disease (24, 29). Beneficial effects of
the inhibition of IFN- production by B. breve, compared to,
e.g., anti-TNF- treatment, may result in a tolerant state with
decreased Th1 immune responses in the gut, whereas other
(e.g., IL-1	- and TNF--driven) immune pathways remain in-
tact, thereby sustaining immunocompetence of the host. How-
ever, further in vivo studies need to be performed to confirm
these findings and to assess the effect on relevant animal mod-
els, such as experimental colitis.
In conclusion, the observed differences in the capacity to
induce cytokine secretion in human primary immune cells be-
tween the Bifidobacterium and Lactobacillus strains is most
likely due to the differential recognition by TLRs. TLR9 me-
diates proinflammatory signals induced by B. breve, L. rham-
FIG. 5. Cytokine production capacity for IL-10 and IFN- by
PBMCs obtained from healthy volunteers and stimulated with the
bacterial strains for 48 h together with a TLR9 blocking agent.
Values are means  SEM; n  6; *, P 
 0.05.
FIG. 6. Cytokine production capacity for TNF-, IL-1	, and IL-6
by PBMCs obtained from healthy volunteers or CD patients homozy-
gous for the frameshift (fs) mutation in NOD2 (1007fsinsC) and stim-
ulated with the bacterial strains for 24 h. Values are means  SEM;
n  4.
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nosus, and L. casei. In contrast, TLR2 exerts inhibitory effects
upon recognition of B. breve but not lactobacilli. It is to be
hoped that these data would contribute to the decision for a
deliberate choice on what probiotic to use in a given applica-
tion.
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